ArticleNeuro-oncology practice2026
Comparative analysis of outcome, recurrence patterns, and dosimetry in glioblastoma patients treated according to RTOG versus EORTC contouring guidelines.
Article in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimal radiotherapy target volume delineation for glioblastoma (GBM) remains debated, with distinct guidelines from the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Direct comparisons of clinical outcomes based on these guidelines are lacking. This study compared overall survival (OS), progression-free survival (PFS), functional status, and dosimetry in GBM patients treated per RTOG or EORTC protocols at a single institution. Methods: We retrospectively analyzed 149 patients with isocitrate dehydrogenase (IDH) wildtype, CNS WHO grade 4 GBM treated with chemoradiotherapy (60 Gy) per RTOG ( Results: No significant difference was found between groups for OS (median 17.0 months, Conclusions: While RTOG and EORTC guidelines yielded comparable survival outcomes, the RTOG protocol was associated with larger irradiated volumes, higher OAR exposure, and greater decline in early post-treatment performance status. These findings support the clinical relevance of volume-sparing strategies in GBM radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.